A new chapter unfolds in the cross-border M&A between ICL and CRO sectors. On November 13, 2024, Adicon Holdings Limited, a leading third-party medical testing provider in China, announced that its wholly-owned subsidiary plans to acquire 100% equity of Crown Bioscience from JSR Life Sciences for $204 million (approximately 1.5 billion yuan).
A mid-sized securities analyst in South China noted that this deal exemplifies the accelerating capital consolidation trend in the CRO sector in 2024. It not only marks Adicon’s strategic shift from a pure diagnostic service provider to an integrated global laboratory services platform but also reflects broader industry dynamics.
**Structured Earn-Out Acquisition** Public records show that Crown Bioscience, a global CRO specializing in oncology and immuno-oncology, brings core value through its capabilities in drug discovery, preclinical, and translational research. Meanwhile, Adicon, one of China’s top three independent clinical laboratory (ICL) service providers, has long dominated the hospital and medical check-up testing market with its network of 32 self-operated labs. Prior to the deal, the two companies had established stable upstream-downstream collaborations.
The transaction structure emphasizes risk control, adopting a tiered earn-out payment model: an initial adjustable upfront payment of $120 million, with the remaining $84 million tied to future performance. Specifically, if Crown Bioscience achieves adjusted EBITDA of $18.9 million in 2025, Adicon will pay an additional $40 million. If adjusted EBITDA exceeds $26 million by 2027, another $44 million plus 5% simple interest will be due. Conversely, if performance falls below $13.5 million in 2025 or $20 million in 2027, the corresponding payments will be waived.
"This payment structure secures strategic positioning while mitigating financial risks through performance-based conditions," an industry analyst remarked. For Adicon, the acquisition is not merely a financial investment but a pivotal step in transitioning from a medical testing provider to a drug R&D participant. Post-acquisition, Crown Bioscience will operate independently, retaining its scientific strengths and global client base while leveraging Adicon’s channels and capital to expand its business.
**CRO Sector Consolidation Accelerates** Adicon’s move is not isolated. In 2024, the CRO sector has witnessed multiple high-profile deals, signaling rapid industry consolidation. Earlier this year, WuXi AppTec sold its core clinical CRO businesses (HD Biosciences and WuXi Clinical) for 2.8 billion yuan to a Hillhouse Capital-backed entity, also incorporating performance-based earn-outs for 2026–2028. In late 2022, Hillhouse acquired Australia’s George Clinical, a CRO specializing in Asia-Pacific multinational trials, underscoring institutional confidence in the sector.
**Market Expansion and Value Logic** The surge in M&A activity is driven by the CRO sector’s expanding market and clear value proposition. According to Hua Jing Industrial Research Institute, the global CRO market grew from $58.2 billion in 2019 to $84.7 billion in 2023, with a CAGR of 9.83%, and is projected to exceed $93.5 billion by 2025. China’s market grew even faster, surging from 47.8 billion yuan to 101.4 billion yuan during the same period, boasting a 19.35% CAGR and emerging as a key growth engine.
Rising R&D costs in biopharma further fuel demand. Deloitte estimates that the median cost of developing a new drug climbed from $1.3 billion in 2013 to $2.3 billion in 2022, with clinical trials accounting for 60% of total expenses. Outsourcing R&D has become a cost-saving strategy for pharmaceutical firms, creating a stable demand base for CROs.
The 2023 biotech funding winter also pressured valuations of quality CRO assets, presenting a rare "value洼地" (valuation trough) for investors. "Counter-cyclical investments at low valuations could yield significant returns once funding rebounds," a healthcare-focused private equity executive noted.
**Strategic Integration Trends** The deeper rationale behind this M&A wave lies in traditional healthcare providers extending into the drug R&D value chain. Globally, similar transformations have occurred: in 2014, LabCorp acquired Covance for $6.1 billion, integrating clinical testing with drug development to build a $22 billion market cap business. In 2015, Quest Diagnostics partnered with Quintiles (now IQVIA) to form a central lab joint venture.
For Chinese ICL firms, cross-border CRO acquisitions are a strategic necessity amid slowing domestic ICL growth and centralized procurement pressures. Pre-deal, 98.7% of Adicon’s revenue came from ICL services, with only 1.2% from CROs. The Crown Bioscience acquisition is expected to contribute 28% to group revenue, diversifying its business mix.
Moreover, the deal enables Adicon to establish an end-to-end service chain spanning early drug discovery, preclinical evaluation, and clinical testing validation. Crown Bioscience derives 80% of its revenue from欧美 markets, serving 95% of the top 20 global oncology pharma firms and over 1,100 biotech companies—a springboard for Adicon’s overseas expansion.
"With Crown Bioscience’s world-class CRO capabilities, Adicon will extend its footprint across the entire global healthcare value chain," said Adicon Chairman and Carlyle Asia Healthcare head Yang Ling, aligning with the company’s vision to become a trusted partner in biopharma innovation and precision testing.
As more players join the cross-sector consolidation trend, the CRO industry’s competitive landscape is poised for profound transformation.
Comments